Tim Casey

Diabetes Support Program with Peers versus Community Health Workers
08/18/2014
San Francisco—Patients with type 2 diabetes who participated in a 6-month diabetes self-management education program followed by a 12-month peer-led or community health worker-led diabetes self-management support program maintained their...
San Francisco—Patients with type 2 diabetes who participated in a 6-month diabetes self-management education program followed by a 12-month peer-led or community health worker-led diabetes self-management support program maintained their...
San Francisco—Patients with type...
08/18/2014
First Report Managed Care
State Medicaid Directors Discuss Expansion
04/17/2014
Falls Church—When President Barack Obama signed the Patient Protection and Affordable Care Act (ACA) into law in March 2010, the legislation included a provision in which the federal government would stop making payments to states if they did...
Falls Church—When President Barack Obama signed the Patient Protection and Affordable Care Act (ACA) into law in March 2010, the legislation included a provision in which the federal government would stop making payments to states if they did...
Falls Church—When President...
04/17/2014
First Report Managed Care
Complications Associated with Surgery for Bladder Cancer
10/23/2013
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of...
10/23/2013
First Report Managed Care
Treating Castrate-Resistant Prostate Cancer
06/26/2013
Orlando—Although the prevalence of prostate cancer is stable, it remains the most common cancer for men. The introduction of new therapies has led to improved survival rates, but most men must take several agents to treat the disease,...
Orlando—Although the prevalence of prostate cancer is stable, it remains the most common cancer for men. The introduction of new therapies has led to improved survival rates, but most men must take several agents to treat the disease,...
Orlando—Although the prevalence...
06/26/2013
First Report Managed Care
Phase 1/2 Trial of MLN9708 for Multiple Myeloma
02/14/2013
Atlanta—Patients with previously untreated multiple myeloma, who took the investigational agent MLN9708 in combination with lenalidomide and dexamethasone, responded well to the drug regimen and tolerated the treatment, according to a phase...
Atlanta—Patients with previously untreated multiple myeloma, who took the investigational agent MLN9708 in combination with lenalidomide and dexamethasone, responded well to the drug regimen and tolerated the treatment, according to a phase...
Atlanta—Patients with previously...
02/14/2013
First Report Managed Care
Lubiprostone and Opioid-Induced Bowel Dysfunction
10/22/2012
Phoenix—A randomized phase 3, multicenter, double-blind, placebo-controlled study of patients with opioid-induced bowel dysfunction (OBD) who took lubiprostone had a statistically significant higher spontaneous bowel movement (SBM) response...
Phoenix—A randomized phase 3, multicenter, double-blind, placebo-controlled study of patients with opioid-induced bowel dysfunction (OBD) who took lubiprostone had a statistically significant higher spontaneous bowel movement (SBM) response...
Phoenix—A randomized phase 3,...
10/22/2012
First Report Managed Care
Afatinib Effective in Treating Late-Stage NSCLC
07/23/2012
Chicago—Patients with advanced stage non–small cell lung cancer (NSCLC) who took the investigational oral agent afatinib had a significantly longer progression-free survival compared with those who received a standard combination chemotherapy...
Chicago—Patients with advanced stage non–small cell lung cancer (NSCLC) who took the investigational oral agent afatinib had a significantly longer progression-free survival compared with those who received a standard combination chemotherapy...
Chicago—Patients with advanced...
07/23/2012
First Report Managed Care
Treating Osteoporosis in Postmenopausal Women
02/22/2012
New Orleans—According to an analysis of clinical trials, bazedoxifene is effective as a second-line therapy for postmenopausal women who have osteoporosis, although the drug is not cost-effective compared with raloxifene. Bazedoxifene and...
New Orleans—According to an analysis of clinical trials, bazedoxifene is effective as a second-line therapy for postmenopausal women who have osteoporosis, although the drug is not cost-effective compared with raloxifene. Bazedoxifene and...
New Orleans—According to an...
02/22/2012
First Report Managed Care
Oxymorphone Extended Release Effective, Tolerable for Patients with Depression
10/14/2011
The likelihood of adverse events (AEs) associated with oxymorphone extended release was similar between the depression and no depression groups.
The likelihood of adverse events (AEs) associated with oxymorphone extended release was similar between the depression and no depression groups.
The likelihood of adverse events...
10/14/2011
First Report Managed Care
Saxagliptin as Add-On Therapy to Insulin in Patients with Type 2 Diabetes
08/22/2011
San Diego—A phase 3b trial presented in a poster session at the ADA meeting indicated that adult patients with type 2 diabetes who took 5 mg of saxagliptin once daily as an add-on therapy to insulin (with or without metformin) showed greater...
San Diego—A phase 3b trial presented in a poster session at the ADA meeting indicated that adult patients with type 2 diabetes who took 5 mg of saxagliptin once daily as an add-on therapy to insulin (with or without metformin) showed greater...
San Diego—A phase 3b trial...
08/22/2011
First Report Managed Care

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use